TB-500 is a synthetic peptide derived from the active region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid protein found throughout the human body that plays a critical role in tissue repair, wound healing, and cellular regeneration.
Primary benefits include:
- Accelerated soft tissue and tendon repair
- Enhanced cell migration to injury sites
- Reduced inflammation and decreased scar formation
- New blood vessel formation (angiogenesis)
- Improved flexibility and range of motion
- Potential cardioprotective properties
What Is TB-500?
TB-500 is a synthetic peptide fragment corresponding to the active region of thymosin beta-4, specifically the amino acid sequence Ac-LKKTETQ. Thymosin beta-4 was first isolated from the thymus gland in 1966 by researchers A.L. Goldstein and A. White, though it was later discovered to be present in high concentrations throughout various tissues including the spleen, lungs, brain, and heart.
Research indicates TB-500 promotes cell migration, reduces inflammation, supports angiogenesis, and accelerates recovery from soft tissue injuries. It has gained significant popularity among athletes, bodybuilders, and biohackers seeking enhanced recovery from musculoskeletal injuries, tendon damage, and general tissue repair.
Primary human-use benefits attributed to TB-500 include accelerated wound healing, reduced inflammation, enhanced flexibility, improved muscle recovery, and support for tendon and ligament repair. The peptide has also demonstrated cardioprotective properties in preclinical research, with studies showing it can reduce infarct size and improve cardiac function following myocardial injury.
How It Works
Actin Regulation and Cell Migration
The primary mechanism of TB-500 centers on its ability to regulate actin, a protein essential for cell structure and movement. By binding to G-actin (globular actin) and blocking actin polymerization, TB-500 promotes the reorganization of the cellular cytoskeleton, which is critical for cell migration to injury sites.
Anti-Inflammatory Effects
TB-500 demonstrates significant anti-inflammatory properties through multiple pathways. Research has shown that thymosin beta-4 sulfoxide, produced by monocytes in response to certain stimuli, blocks neutrophil chemotaxis and possesses potent anti-inflammatory activity. The peptide also reduces macrophage infiltration at injury sites, which helps modulate the inflammatory response and may contribute to decreased scar formation and fibrosis.
Angiogenesis Promotion
TB-500 supports the formation of new blood vessels, which is essential for delivering oxygen and nutrients to healing tissues. Studies have demonstrated that the peptide promotes endothelial cell migration and differentiation, contributing to improved vascularization of damaged areas.
Stem Cell Mobilization
Research indicates TB-500 promotes the mobilization, migration, and differentiation of stem and progenitor cells, which can form new blood vessels and regenerate tissue.
Dosage Protocols
No standardized dosing protocols have been established through clinical trials for human use. The following protocols are derived from anecdotal reports and extrapolation from research settings.
Loading Phase: Conservative protocols recommend 1.0–1.5 mg administered subcutaneously or intramuscularly twice weekly (2–3 mg weekly total), for 4–6 weeks. Some community protocols use higher doses, but no human clinical trial data exists to support specific loading doses.
Maintenance Phase: Following the loading period, dosing typically reduces to 1–2 mg once weekly to maintain therapeutic effects.
Cycling Considerations:
- Typical active use: 4–6 weeks
- Common protocol: 4–6 weeks on, 2–4 weeks off before resuming if needed
- Chronic conditions may require extended or adjusted protocols
How to Use / Administration Methods
TB-500 is typically administered via subcutaneous or intramuscular injection. Subcutaneous injections are most common and involve injecting into the fatty tissue beneath the skin, often in the abdominal area, thigh, or upper arm.
Administration Guidelines:
- Start with a lower dose and gradually increase to the target dose to assess tolerance
- Rotate injection sites regularly to reduce irritation and prevent tissue damage at any single location
- Injections are typically performed once daily during loading phases or 2–3 times weekly during maintenance
- Some users inject closer to the injury site, though the peptide's systemic distribution means this may not be necessary
- Proper sterile technique is essential, including cleaning the injection site with alcohol, using new sterile needles for each injection, and ensuring hands are clean before handling supplies
Results Timelines
Weeks 1–2:
- Some users report initial reductions in inflammation and mild improvements in comfort at injury sites
Weeks 2–4:
- Many individuals begin noticing improvements in mobility, recovery speed, and energy levels
Weeks 4–8:
- More substantial improvements in tissue repair, flexibility, and functional recovery are commonly reported during this period
Months 2–6:
- Long-term benefits often continue to build with consistent use, particularly for chronic injuries or conditions requiring extended healing time
Research Evidence
Thymosin beta-4 and its derivatives have been studied in various preclinical and clinical contexts. Phase II clinical trials have evaluated TB4 for dermal wound healing, with results demonstrating accelerated repair in patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds. These trials concluded that TB4 is safe, well-tolerated, and shows promise for skin regeneration applications.
Cardiac Research: Studies in animal models demonstrated that TB4 administration following coronary artery ligation enhanced myocyte survival and improved cardiac function. Research in porcine models of ischemic heart disease has further supported the therapeutic potential of thymosin beta-4 for cardiac applications.
Neurological Research: Neurological research has explored TB4's neuroprotective and neurorestorative effects, with studies suggesting potential applications for traumatic brain injury treatment.
Key Limitation: Most human-relevant research has focused on the parent compound thymosin beta-4 rather than the TB-500 fragment specifically, and large-scale clinical trials for musculoskeletal applications in humans remain limited.
Stacking
TB-500 + BPC-157 — "Wolverine Stack"
This combination is popular because the peptides work through complementary mechanisms. BPC-157 tends to provide more localized healing effects and stimulates collagen synthesis, while TB-500 offers systemic recovery support and promotes cellular migration and angiogenesis. When stacked, typical protocols involve standard doses of each peptide administered separately, often at different times of day.
Common Wolverine Stack Protocol:
- TB-500: 2.0–2.5 mg twice weekly (loading), then 2.0–2.5 mg weekly (maintenance)
- BPC-157: 250–500 mcg daily
Additional Stack Options:
- Growth hormone secretagogues (such as Ipamorelin or CJC-1295): For systemic anabolic and regenerative support
- GHK-Cu: For enhanced collagen production and comprehensive healing support
Reconstitution, Storage & Prep
TB-500 typically comes as a lyophilized (freeze-dried) powder that requires reconstitution before use.
Reconstitution Process:
- Allow vial to reach room temperature
- Add bacteriostatic water to the vial containing the lyophilized powder
- Inject the water slowly along the inside wall of the vial rather than directly onto the powder
- Gently swirl — do not shake vigorously — until the powder is fully dissolved
Common Reconstitution Ratio:
- 5 mg TB-500 + 2 mL bacteriostatic water = 2.5 mg/mL (2.5 mg per 1 mL / 100 units)
Storage Guidelines:
- Unreconstituted: Refrigerated or stored in a cool, dry place; stable at room temperature for short periods
- Reconstituted: Refrigerated at 2–8°C (36–46°F), stable for 3–4 weeks
- Never freeze reconstituted peptide solutions
- Protect from light and heat exposure
Side Effects
TB-500 is generally considered well-tolerated based on available research and anecdotal reports. Thymosin beta-4 has demonstrated a favorable safety profile in clinical trials, with minimal reported adverse effects.
Commonly Reported:
- Injection site reactions including temporary redness, irritation, or mild discomfort
- Temporary fatigue or lethargy, particularly during initial use
- Headaches (occasionally reported)
Potential Concerns: Laboratory studies have suggested that thymosin beta-4 may play a role in helping certain cancers spread, though no direct evidence links TB-500 use to cancer development in humans. Long-term safety data in humans remains limited, and the effects of extended use are not well characterized.
Legal Status / FDA
TB-500 is not approved by the U.S. Food and Drug Administration (FDA) for any medical use in humans. The FDA has classified TB-500 (thymosin beta-4) as a "Substance with Safety Concerns," prohibiting its use in compounding pharmacies under the 503A and 503B bulk drug substance regulations.
Key Regulatory Points:
- Not FDA-approved for any medical indication
- Cannot legally be sold as a drug, food, or dietary supplement for human consumption
- Recent FDA actions have restricted the compounding and prescribing of many peptides, including TB-500, limiting access through traditional medical channels
- Legally purchased and possessed as a "research chemical" not intended for human consumption
- Not DEA-scheduled; possession is not illegal
Sports / WADA
TB-500 and thymosin beta-4 are prohibited substances under the World Anti-Doping Agency (WADA) Prohibited List. They fall under categories S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics).
Thymosin beta-4 and its derivatives, including TB-500, were explicitly added as examples of prohibited substances in the 2018 WADA Prohibited List update.
Key Anti-Doping Points:
- Prohibited both in-competition and out-of-competition
- Athletes subject to WADA-compliant testing programs cannot use TB-500 at any time during their competitive careers
- Positive tests carry severe penalties including competition bans and disqualification of results
- Applies to all sports organizations following WADA regulations
Conclusion
TB-500 represents a compelling peptide option for individuals seeking enhanced tissue repair and recovery support. Its mechanisms — including actin regulation, anti-inflammatory effects, angiogenesis promotion, and stem cell mobilization — provide a multi-faceted approach to healing that has generated significant interest in both research and practical applications.
While preclinical research and early clinical trials have demonstrated promising results, particularly for wound healing and cardiac applications, the lack of large-scale human trials for musculoskeletal uses means that much of the evidence supporting TB-500's benefits remains preliminary. Users should approach this peptide with appropriate caution, understanding both its potential benefits and the limitations of current scientific knowledge.
For those who choose to use TB-500, proper sourcing, reconstitution, storage, and administration practices are essential for safety and efficacy. Consultation with a knowledgeable healthcare provider is advisable, particularly for individuals with pre-existing health conditions or those taking other medications.